# Liposomal Bupivacaine Versus Standard Bupivacaine in the Adductor Canal for Total Knee Arthroplasty

> **NCT03182933** · PHASE4 · TERMINATED · sponsor: **University of Wisconsin, Madison** · enrollment: 64 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** Peripheral Nerve Blockade
- **BEHAVIORAL:** 10 meter walk test on post-operative day 1
- **OTHER:** In person and over the phone questionnaire
- **DEVICE:** Force transduction of quadriceps strength

## Key facts

- **NCT ID:** NCT03182933
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-30
- **Primary completion:** 2018-07-16
- **Final completion:** 2018-07-16
- **Target enrollment:** 64 (ACTUAL)
- **Why stopped:** Terminated due to surgeon preferences
- **Last updated:** 2019-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03182933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03182933, "Liposomal Bupivacaine Versus Standard Bupivacaine in the Adductor Canal for Total Knee Arthroplasty". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03182933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*